A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin

Am J Clin Oncol. 1990 Oct;13(5):416-9. doi: 10.1097/00000421-199010000-00010.

Abstract

Intravenous bolus mitomycin was given at a dose of 10-12 mg/m2 to patients with epithelial ovarian cancer resistant to cisplatin or carboplatin. There were three (12%) partial responses and no complete responses in the 25 patients so treated.

MeSH terms

  • Adult
  • Aged
  • Carboplatin / therapeutic use*
  • Carcinoma / drug therapy*
  • Cisplatin / therapeutic use*
  • Drug Evaluation
  • Drug Resistance
  • Female
  • Humans
  • Leukopenia / chemically induced
  • Middle Aged
  • Mitomycins / adverse effects
  • Mitomycins / therapeutic use*
  • Ovarian Neoplasms / drug therapy*
  • Remission Induction
  • Thrombocytopenia / chemically induced

Substances

  • Mitomycins
  • Carboplatin
  • Cisplatin